Comparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization
|
|
- Quentin Patterson
- 5 years ago
- Views:
Transcription
1 Comparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization Peter Kovacs, M.D., a Timea Kovats, M.D., a Artur Bernard, M.D., a Janos Zadori, M.D., b Gabor Szmatona, M.D., a and Steven G. Kaali, M.D. a a Kaali Institute IVF Center, Budapest, and b Kaali Institute IVF Center, Szeged, Hungary Objective: To study serum and follicular fluid (FF) hormone levels after the administration of urinary or recombinant hcg to initiate the final stages of oocyte maturation during IVF. Design: Prospective randomized study between 250 mg of recombinant hcg and 7,500 IU of urinary hcg as the final trigger of ovulation during IVF. Setting: Private IVF center. Patient(s): Infertile women undergoing IVF/intracytoplasmic sperm injection (ICSI) using the long protocol and recombinant FSH. Intervention(s): IVF treatment. Serum and FF hormone measurements on the day of oocyte collection. Main Outcome Measure(s): Serum and FF E 2, P, hcg, and T levels. Result(s): Stimulation parameters, serum and follicular E 2, P, T, and hcg levels were similar in the recombinant and urinary hcg groups. The number of oocytes retrieved from follicles >14 mm, the proportion of mature oocytes, fertilization rate, and pregnancy rate (PR) were also comparable. Conclusion(s): Recombinant and urinary hcg provided similar serum and follicular hormonal environments during the final stages of oocyte maturation. The IVF outcome parameters were also comparable. The two medications appear to be equally effective. (Fertil Steril Ò 2008;90: Ó2008 by American Society for Reproductive Medicine.) Key Words: Recombinant, urinary, human chorionic gonadotropin, follicular fluid, steroid, serum During a spontaneous menstrual cycle a preovulatory LH surge initiates the ovulatory process. As a result of the LH surge the oocytes complete meiosis I and enter meiosis II, the cumulus oocyte complex separates from the follicle wall and the process resulting in the release of the oocyte cumulus complex is started (1). During an IVF cycle premature luteinization could negatively affect treatment outcome. If the follicles rupture prematurely, oocytes cannot be collected. To prevent premature LH surges GnRH agonist or antagonist is combined with gonadotropins. Both GnRH preparations successfully prevent premature ovulation. Therefore to collect mature eggs for fertilization the LH surge needs to be induced medically (2, 3). In cycles without down-regulation and in cycles where a GnRH antagonist is used to prevent the premature LH surge both GnRH agonist or hcg can be administered for this purpose (4, 5). In GnRH agonist down-regulated cycles hcg has to be administered before the retrieval. Human chorionic gonadotropin and LH have a lot of similarities in their structure, therefore hcg is capable of inducing the necessary changes through the LH receptor (6). Received August 22, 2007; revised and accepted October 9, Presented at the 63 rd Annual Meeting of the American Society for Reproductive Medicine, October 13 17, 2007, Washington, D.C. Reprint requests: Peter Kovacs, M.D., Kaali Institute IVF Center, Istenhegyi u 54/a, 1125 Budapest, Hungary (FAX: ; peterkovacs1970@hotmail.com). The growing follicle requires a unique endocrine environment to develop a mature egg. Steroid hormones and various peptides produced both locally and at distant sites are responsible for providing an optimal nourishing milieu. Changes in this environment might lead to oocytes that are less likely to fertilize successfully or might result in poorer quality embryos. Previous studies have shown that an environment rich in androgens is unfavorable for the developing oocyte. Xia and Younglai (7) found that when the follicular fluid (FF) E 2 -to-t ratio exceeded 200, significantly more high quality (grades 3, 4) oocytes were obtained. Higher FF E 2 -to-t ratio was reported in IVF cycles that resulted in a pregnancy (8). Significantly higher FF P-to-E 2 ratio was measured in follicles from which the oocyte was successfully fertilized (9). Kreiner et al. (10) observed that FF E 2 and P levels tended to be within a given range in IVF cycles that resulted in a pregnancy. More recently a follicular environment richer in E 2 was reported with the use of highly purified hmg when it was compared to recombinant FSH. This group also reported that the FF E 2 -to-t ratio was higher in those follicles that provided an egg resulting in a pregnancy (11). Although the follicular environment is primarily influenced by the type of gonadotropin the follicle is exposed to during the follicular phase, the hcg injection that triggers the luteinizing changes also has a significant influence on this environment /08/$34.00 Fertility and Sterility â Vol. 90, No. 6, December doi: /j.fertnstert Copyright ª2008 American Society for Reproductive Medicine, Published by Elsevier Inc.
2 For decades hcg derived from urine was available and was used during IVF cycles. More recently recombinant hcg became available. Several clinical studies have shown that the two hcg preparations result in a similar number of oocytes, clinical pregnancies, ongoing pregnancies, delivery and miscarriage rates (12, 13). In our study we were interested in the follicular hormonal environment with the available urinary and recombinant hcg preparations. As secondary outcomes, we were also interested in any possible association between the hormonal values/ratios and oocyte quality, fertilization, embryo development, and pregnancy rates (PR). MATERIALS AND METHODS In this prospective, randomized multicenter trial, Institutional Review Board (IRB) approval was obtained (SZTE Albert Szent-Gyorgyi School of Medicine 106/2006) and all participants signed informed consent before entering the study. Sixty women were randomized to receive either 250 mg of recombinant hcg SC (Ovitrelle, Serono, Italy) or 7,500 IU of urinary hcg IM (Choragon, Ferring, Germany) to induce the final maturation of the oocytes. Block randomization (blocks of 2) was used to allocate patients to the two hcg preparations. Patients were randomized when they came in for the suppression check during the GnRH agonist. The study was conducted between December 2006 and April Infertile women less than 40 years of age with regular menstrual cycles were eligible to participate. The baseline FSH level had to be <12 IU/L and the uterine cavity had to be intact. Couples with severe male factor infertility (need for surgical sperm extraction or use of donor sperm) were excluded. Couples with previous poor response to stimulation (<3 oocytes, cancelled cycle, use of high dose of gonadotropins [>300 IU/day]) and those with more than two failed previous IVF cycles were also excluded. Multiple ovarian follicle development was achieved using the GnRH agonist long protocol and recombinant FSH. The GnRH agonist (0.5 ml of Suprefact SC; Aventis Pharma, Germany) was started in the luteal phase of the previous cycle. After days of GnRH agonist administration, once suppression was confirmed, stimulation with 150 IU of recombinant FSH (Gonal-F, Serono, Italy) was started. The first ultrasound was performed on day 6 of stimulation. The dose of the gonadotropin could be increased or decreased at this point based on response. Ultrasound and, if required, serum E 2 measurements were used to monitor follicle growth. Once two leading follicles reached 17 mm in diameter recombinant or urinary hcg was administered to induce final follicular maturation. Transvaginal oocyte retrieval was scheduled hours after this final injection. After the retrieval the oocytes were evaluated for maturity and conventional insemination or if needed intracytoplasmic sperm injection (ICSI) was used for fertilization. Fertilization was assessed the next day. The embryos were cultured for 3 5 days before the transfer. The day of transfer and the number of embryos transferred were decided by the physician based on patient and cycle characteristics. The luteal phase was supported by 600 mg of vaginal micronized P in divided doses (Utrogestan, Lab Besius, France). Twelve days after the transfer a serum b-hcg was measured. At 6 weeks and at 8 weeks a pelvic ultrasound was performed to monitor the early pregnancy. Progesterone supplementation was continued until week 9 of pregnancy. Serum and Follicular Fluid Samples On the day of the oocyte retrieval serum and FF were collected. Blood was drawn from the antecubital vein. The specimen was spun for 10 minutes at 3,000 rpm to separate the serum and cellular components. Serum measurement for E 2, P, T, and hcg were carried out with commercially available ELISA assays using an automated system. Follicular fluid was collected from several follicles. Pooled samples were obtained. All bloody samples were discarded. Follicular fluid was also spun for 10 minutes at 3,000 rpm, first to separate the cellular components. Estradiol, P, T, and hcg levels were determined using commercially available ELISA assays. For E 2 and P measurements the samples had to be diluted 1,000 times manually. Data Collection Data was collected for baseline characteristics (age, baseline FSH, E 2 ), stimulation parameters (dose of gonadotropin, type of hcg, number of follicles >14 mm, number of oocytes, rate of mature oocytes [mature MII oocytes/total oocytes retrieved], fertilization rate based on all oocytes and mature oocytes only [fertilized oocytes/all oocytes retrieved, fertilized oocytes/mature MII oocytes retrieved], number of available embryos, proportion of top quality embryos [R6 cells on day 3, <20% fragmentation; top quality embryos/all embryos], number of embryos transferred and cryopreserved), and for treatment outcome. When a positive serum pregnancy test was obtained 12 days after the embryo transfer it was considered a pregnancy. When a pregnancy progressed beyond week 8 and was discharged from our care we considered it an ongoing pregnancy. In addition to serum and FF measurements, the ratios of E 2 -to-t and E 2 -to-p were compared. Statistical Methods Student s t-test was used to compare quantitative variables and c 2 test to compare proportions between the different outcomes with recombinant and urinary hcg. A P<.05 was considered significant. RESULTS Sixty patients were randomized. Baseline characteristics were comparable in the two groups (Table 1). None of the cycles were cancelled during stimulation and all cycles ended with embryo transfer Kovacs et al. Recombinant and urinary hcg induce similar effects Vol. 90, No. 6, December 2008
3 Stimulation parameters are also shown in Table 1. The stimulation parameters were similar in both groups. The follicle (>14 mm)-to-egg conversion rates were also similar with the two hcg preparations and the proportion of mature oocytes and fertilization rates were also comparable. Serum and FF hormone values in the two groups are shown in Table 2. Estradiol, P, T, and hcg levels were similar with the two hcg preparations, both in the serum and FF. The overall PR was 51.7 % (31/60). There was no significant difference in the PR (recombinant hcg: 13/30 [43.3%] vs. urinary hcg: 18/30 [60%]; P ¼.301), ongoing PR (recombinant hcg: 11/30 [36.6%] vs. urinary hcg: 15/30 [50%]; P ¼.73), and multiple gestation rate (recombinant hcg: 2/13 [15.3%] vs. urinary hcg: 6/18 [33.3%]; P ¼.395) in the two groups. DISCUSSION Normal follicle development requires a very specific microenvironment. Although the final stages of folliculogenesis primarily depend on the availability of FSH and LH, various growth factors, peptide hormones, and cytokines contribute to this process. The last step before ovulation is the LH surge. The surge is needed for the completion of meiosis I, for the release of the oocyte, and also for the transition to corpus luteum (CL) function. As a result of the LH surge E 2 production is decreased in the granulosa cells (GC) and P synthesis increases at the expense of androgen synthesis in the theca cells (1). During an IVF cycle the spontaneous LH surge is blocked and when needed the LH surge is induced with either GnRH agonist or hcg (4, 5). The hcg has a similar structure to LH and is capable of binding to the LH receptor and to mediate an effect through it (6). For a long time hcg was only available after purification from urine. More recently a recombinant form became available. Several studies have compared their clinical effects. Driscoll et al. (14), in a randomized study, found that the number of oocytes collected per follicles aspirated, number of mature oocytes, fertilized oocytes, and number of cleaving embryos were similar with 5,000 IU of urinary hcg or 250 mg of recombinant hcg. More recently several meta-analyses and review articles confirmed similar effects (12, 13). It has been previously reported that the steroid and peptide microenvironment within the follicle reflects on the competence of the egg retrieved from that follicle. It was shown that those IVF cycles where the FF E 2 and E 2 -to-p ratio was in a given range were more likely to result in pregnancy (10). Other studies have also observed a correlation between steroid hormone ratios and fertilization rates during IVF cycles (9). Andersen (8) studied the association between steroid and peptide hormone levels in FF, and oocyte maturity, fertilization, embryo cleavage, and pregnancy outcome. He also demonstrated in his study that rather than individual steroid levels, the FF E 2 -to-t ratio was the best predictor of successful implantation. Higher ratio (suggesting better androgen-to-estrogen [E] conversion) was associated with higher implantation rate (8). Another group studied the correlation between oocyte quality (assessed by the status of the TABLE 1 Demographic and stimulation characteristics in the recombinant and urinary hcg groups. Recombinant hcg group Urinary hcg group Age (y) Baseline FSH (IU/L) Baseline E 2 (pmol/l) Gonadotropin (IU) Follicles >14 mm Oocytes MII oocytes Rate of mature MII oocytes (%) Fertilized oocytes Fertilization rate per all oocytes (%) Fertilization rate per mature (MII) oocytes (%) No. of embryos No. of top quality embryos Rate of top quality embryos (%) No. of embryos transferred No. of embryos frozen Note: Values are expressed as mean SEM. Using t test for comparison at P<.05 none of the differences are significant. Kovacs. Recombinant and urinary hcg induce similar effects. Fertil Steril Fertility and Sterility â 2135
4 TABLE 2 Serum and follicular fluid hormone levels on the day of the retrieval in the two experimental groups. Recombinant hcg group Urinary hcg group Serum E 2 (pmol/l) 4, , P (nmol/l) hcg (IU/L) T (nmol/l) Follicular fluid E 2 (pmol/l) 2,717, ,649 2,154, ,745 P (nmol/l) 35,273 5,076 37,371 5,080 hcg (IU/L) T (nmol/l) E 2 :T 171, , , ,716.5 E 2 :P Note: Values are expressed as mean SEM. Using t test for comparison at P<.05 none of the differences are significant. Kovacs. Recombinant and urinary hcg induce similar effects. Fertil Steril polar body and the size of the perivitelline space) and follicular steroid hormone levels. They measured higher E 2 -to-t ratio in those follicles that contained higher quality oocytes (7). Tessier et al. (15) showed that individual steroid levels also differed between meiotically competent and incompetent oocytes. The concentration of E 2 and P was significantly higher in follicles that contained meiotically competent oocytes, whereas the concentration of T was higher in follicles that contained meiotically incompetent oocytes in both normal and women with PCOS. The purpose of our study was to evaluate whether urinary and recombinant hcg were equally capable of initiating the conversion of follicular activity to CL activity and thereby whether they are equally effective in providing the necessary hormonal environment for the oocytes before retrieval. We did not evaluate individual follicles but were interested in the overall performance of the two drugs, therefore we used pooled samples. Patients with similar baseline characteristics, treated with the same stimulation protocol and similar amount of gonadotropin were analyzed. We found that both the individual follicular steroid and hcg levels, as well as the ratios of E-to-T and E-to-P were similar in the two protocols. In addition, we found that eggs could be obtained from a similar percentage of large (>14 mm) follicles. We did not observe any difference in the embryology parameters and in the treatment outcome. Our results further support the similar effects of recombinant and urinary hcg. They not only lead to similar clinical effects, but the biochemical changes induced in the follicles are comparable. In summary, we found similar biochemical and clinical outcome with recombinant and urinary hcg preparations during IVF treatment of normal responder patients. Because the use of recombinant preparations is easier for the patients (SC administration allowing self-injection) and the batchto-batch consistency is presumably better, its use is preferable over urinary preparations. REFERENCES 1. Geugeon A. Regulation of ovarian follicular development in primates: facts and hypothesis. Endocrinol Rev 1996;17: Hofmann GE, Bergh PA, Guzman I, Masuku S, Navot D. Premature luteinization is not eliminated by pituitary desensitization with leuprolide acetate in women undergoing gonadotrophin stimulation who demonstrated premature luteinization in a prior gonadotrophin-only cycle. Hum Reprod 1993;8: Diedrich K, Diedrich C, Santos E, Zoll C, al-hasani S, Reissmann T, et al. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod 1994;9: Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes JM. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril 1991;56: Abdalla HI, Ah-Moye M, Brinsden P, Howe DL, Okonofua F, Craft I. The effect of the dose of human chorionic gonadotropin and the type of gonadotropin stimulation on oocyte recovery rates in an in vitro fertilization program. Fertil Steril 1987;48: Pierce JG, Parsons TF. Glycoprotein hormones: structure and function. Annu Rev Biochem 1981;50: Xia P, Younglai EV. Relationship between steroid concentrations in ovarian follicular fluid and oocyte morphology in patients undergoing intracytoplasmic sperm injection (ICSI) treatment. J Reprod Fertil 2000;118: Andersen CY. Characteristics of human follicular fluid associated with successful conception after in vitro fertilization. J Clin Endocrinol Metab 1993;77: Enien WM, el Sahwy S, Harris CP, Seif MW, Elstein M. Human chorionic gonadotrophin and steroid concentrations in follicular fluid: the relationship to oocyte maturity and fertilization rates in stimulated and natural in-vitro fertilization cycles. Hum Reprod 1995;10: Kreiner D, Liu HC, Itskovitz J, Veeck L, Rosenwaks Z. Follicular fluid estradiol and progesterone are markers of preovulatory oocyte quality. Fertil Steril 1987;48: Kovacs et al. Recombinant and urinary hcg induce similar effects Vol. 90, No. 6, December 2008
5 11. Smitz J, Andersen AN, Devroey P, Arce J-C, for the MERIT Group. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. Hum Reprod 2007;22: Al-Inany H, Aboulghar AM, Mansour RT, Proctor M. Recombinant versus urinary gonadotrophins for triggering ovulation in assisted conception. Hum Reprod 2005;20: Ludwig M, Doody KJ, Doody KM. Use of recombinant human chorionic gonadotropin in ovulation induction. Fertil Steril 2003;79: Driscoll GL, Tyler JP, Hangan JT, Fisher PR, Birdsall MA, Knight DC. A prospective, randomized, controlled, double-blind, double-dummy comparison of recombinant and urinary HCG for inducing oocyte maturation and follicular luteinization in ovarian stimulation. Hum Reprod 2000;15: Tessier MP, Chable H, Paulhac S, Aubard Y. Comparison of follicle steroidogenesis from normal and polycystic ovaries in women undergoing IVF: relationship between steroid concentrations, follicle size, oocyte quality and fecundability. Hum Reprod 2000;15: Fertility and Sterility â 2137
Female Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF
Female Reproductive Physiology Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF REFERENCE Lew, R, Natural History of ovarian function including assessment of ovarian reserve
More informationLuteal phase rescue after GnRHa triggering Progesterone and Estradiol
Luteal phase rescue after GnRHa triggering Progesterone and Estradiol L. Engmann University of Connecticut Disclaimer Fertility Speaker Bureau Merck Pharmaceuticals Introduction GnRH agonist is effective
More informationDoes triggering ovulation by 5000 IU of uhcg affect ICSI outcome? *
Middle East Fertility Society Journal Vol. 11, No. 2, 2006 Copyright Middle East Fertility Society Does triggering ovulation by 5000 IU of uhcg affect ICSI outcome? * Amany A.M. Shaltout, M.D. Mohamed
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Interpreting Follicular Phase Progesterone Ernesto Bosch IVI Valencia,
More informationAgonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M
Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M Record Status This is a critical abstract of an economic
More informationI. ART PROCEDURES. A. In Vitro Fertilization (IVF)
DFW Fertility Associates ASSISTED REPRODUCTIVE TECHNOLOGY (ART) Welcome to DFW Fertility Associates/ Presbyterian-Harris Methodist Hospital ARTS program. This document provides an overview of treatment
More informationRelevance of LH activity supplementation
Relevance of LH activity supplementation in ovulation induction Franco Lisi Servizio di Fisiopatologia della Riproduzione Clinica Villa Europa Roma, Italia Comprehension of the role of LH in follicular
More informationIVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)
34 11 Vol.34 No.11 2014 11 Nov. 2014 Reproduction & Contraception doi: 10.7669/j.issn.0253-3X.2014.11.0892 E-mail: randc_journal@163.com IVF ( 710003) : (H-hMG) - (IVF- ET) : GnRH H-hMG (H-hMG ) (rfsh
More informationFemale Reproductive System. Lesson 10
Female Reproductive System Lesson 10 Learning Goals 1. What are the five hormones involved in the female reproductive system? 2. Understand the four phases of the menstrual cycle. Human Reproductive System
More informationFollicular fluid steroid hormone levels are associated with fertilization outcome after intracytoplasmic sperm injection
Follicular fluid steroid hormone levels are associated with fertilization outcome after intracytoplasmic sperm injection Julie D. Lamb, M.D., a A. Musa Zamah, M.D., Ph.D., a Shehua Shen, M.D., a Charles
More informationProgesterone and clinical outcomes
Synchronization of Slowly Developing Embryos Restores Implantation Success Richard T. Scott, Jr, MD, HCLD Clinical and Scientific Director, Reproductive Medicine Associates of New Jersey Professor and
More informationIs it the seed or the soil? Arthur Leader, MD, FRCSC
The Physiological Limits of Ovarian Stimulation Is it the seed or the soil? Arthur Leader, MD, FRCSC Objectives 1. To consider how ovarian stimulation protocols work in IVF 2. To review the key events
More informationLUTEAL PHASE SUPPORT. Doç. Dr. Nafiye Yılmaz. Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi
LUTEAL PHASE SUPPORT Doç. Dr. Nafiye Yılmaz Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi TAJEV, 2014 1 ART & success *Live birth rate 2 Optimal luteal phase Etiology of luteal phase deficiency
More informationA Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist
1 *, ** * * * ** A Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist Yoon Sung Nam, Nam Keun Kim*, Eun Kyung Kim**, Hyung Min Chung** and Kwang
More informationNeil Goodman, MD, FACE
Initial Workup of Infertile Couple: Female Neil Goodman, MD, FACE Professor of Medicine Voluntary Faculty University of Miami Miller School of Medicine Scope of Infertility in the United States Affects
More informationIntérêt de l hcg et induction de l ovulation. Christophe Blockeel, MD, PhD Centre for Reproductive Medicine, Brussels, Belgium
Intérêt de l hcg et induction de l ovulation Christophe Blockeel, MD, PhD Centre for Reproductive Medicine, Brussels, Belgium Conflict of interest The opinions expressed in this document are the opinions
More informationClinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G.
UvA-DARE (Digital Academic Repository) Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G. Link to publication Citation for published version (APA): Al-Inany,
More informationClinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients
International Reproductive Medicine Volume 2013, Article ID 135258, 4 pages http://dx.doi.org/10.1155/2013/135258 Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin
More informationArticle Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment
RBMOnline - Vol 7. No 2. 185 189 Reproductive BioMedicine Online; www.rbmonline.com/article/900 on web 18 June 2003 Article Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix,
More informationInfertility treatment
In the name of God Infertility treatment Treatment options The optimal treatment is one that provide an acceptable success rate, has minimal risk and is costeffective. The treatment options are: 1- Ovulation
More informationLOW RESPONDERS. Poor Ovarian Response, Por
LOW RESPONDERS Poor Ovarian Response, Por Patients with a low number of retrieved oocytes despite adequate ovarian stimulation during fertility treatment. Diagnosis Female About Low responders In patients
More information10.7 The Reproductive Hormones
10.7 The Reproductive Hormones December 10, 2013. Website survey?? QUESTION: Who is more complicated: men or women? The Female Reproductive System ovaries: produce gametes (eggs) produce estrogen (steroid
More informationPrinciples of Ovarian Stimulation
Principles of Ovarian Stimulation Dr Genia Rozen Gynaecologist and Fertility Specialist Royal Women s Hospital and Melbourne IVF Learning objectives Why ovarian stimulation Recap physiology Ovarian cycle
More information2015 Mar.; 26(1):
Journal of Reproduction & Contraception doi: 10.7669/j.issn.1001-7844.2015.01.0022 2015 Mar.; 26(1):22-30 E-mail: randc_journal@163.com Clinical outcomes of using three gonadatropins and medroxyprogestrone
More informationOriginal Article Effects of a low hcg dose of 2000 IU on clinical outcomes of high-responder women undergoing IVF/ICSI
Int J Clin Exp Med 2016;9(7):14677-14683 www.ijcem.com /ISSN:1940-5901/IJCEM0026636 Original Article Effects of a low hcg dose of 2000 IU on clinical outcomes of high-responder women undergoing IVF/ICSI
More informationPremature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles
Arch Gynecol Obstet (2010) 281:747 752 DOI 10.1007/s00404-009-1248-0 REPRODUCTIVE MEDICINE Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles Esra
More informationRaoul Orvieto. The Chaim Sheba Medical Center Tel Hashomer, Israel. Declared no potential conflict of interest
Raoul Orvieto The Chaim Sheba Medical Center Tel Hashomer, Israel Declared no potential conflict of interest LH in antagonist cycles; is the story really written? Raoul Orvieto M.D. Israel Overview Role
More informationOVULATION INDUCTION. Ori Nevo, M.D., a Talia Eldar-Geva, M.D., Ph.D., b Shahar Kol, M.D., a and Joseph Itskovitz-Eldor, M.D., D.Sc.
FERTILITY AND STERILITY VOL. 79, NO. 5, MAY 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. OVULATION INDUCTION Lower levels
More informationFactors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles
ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2015;42(2):67-71 Factors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles Ju Hee Park
More informationSredišnja medicinska knjižnica
Središnja medicinska knjižnica Kasum M., Kurdija K., Orešković S., Čehić E., Pavičić-Baldani D., Škrgatić L. (2016) Combined ovulation triggering with GnRH agonist and hcg in IVF patients. Gynecological
More informationVanessa N. Weitzman, M.D., Lawrence Engmann, M.D., Andrea DiLuigi, M.D., Donald Maier, M.D., John Nulsen, M.D., and Claudio Benadiva, M.D.
Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol
More informationMenstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
Human Reproduction Vol.21, No.4 pp. 1012 1017, 2006 Advance Access publication December 8, 2005. doi:10.1093/humrep/dei415 Menstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
More information- Meta. : (rfsh); (ufsh); (IVF); : R711.6 : A : X(2015) : hmg( FSH LH) [ufsh, (ufsh-p) (ufsh-hp)] (rfsh) [1] 80, rfsh, 90, :
35 2 Vol.35 No.2 2015 2 Feb. 2015 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2015.02.0099 E-mail: randc_journal@163.com (FSH) - Meta FSH ( 400010) : (IVF) (ICSI) (rfsh) (ufsh) (COS) : PubMed
More informationInterpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used
Interpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used Ellenbogen A., M.D., Shalom-Paz E., M.D, Asalih N., M.D, Samara
More informationArticle Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles
RBMOnline - Vol 13. No 3. 2006 326 330 Reproductive BioMedicine Online; www.rbmonline.com/article/1911 on web 13 June 2006 Article Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist
More information(1.,, ) (2.,,, )
33 11 Vol.33 No.11 2013 11 Nov. 2013 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2013.11.0749 E-mail: randc_journal@163.com IVF-ET 1 2 1 1 1 1 1 (1. 510150) (2. 510150) : (COH) (premature
More informationMilder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization
Milder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization Revelli et al. Reproductive Biology and Endocrinology 2011, 9:25 Presenter: R2 孫怡虹 Background
More informationRafael A. Cabrera, M.D., Laurel Stadtmauer, M.D., Ph.D., Jacob F. Mayer, Ph.D., William E. Gibbons, M.D., and Sergio Oehninger, M.D., Ph.D.
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant
More informationDoes previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?
J Assist Reprod Genet (26) 23:427 431 DOI 1.17/s1815-6-965-x ASSISTED REPRODUCTION Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation
More informationKey words: HCG versus GnRH agonist/ivf-gnrh antagonist cycles/ongoing pregnancy rates/oocyte maturation/rct
Human Reproduction Vol.20, No.10 pp. 2887 2892, 2005 Advance Access publication June 24, 2005. doi:10.1093/humrep/dei150 A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering
More informationAssisted Reproduction. By Dr. Afraa Mahjoob Al-Naddawi
Assisted Reproduction By Dr. Afraa Mahjoob Al-Naddawi Learning Objectives: By the end of this lecture, you will be able to: 1) Define assisted reproductive techniques (ART). 2) List indications for various
More informationThe impact of HMG on follicular fluid hormone levels, embryo quality and IVF outcome
Eastern Journal of Medicine 19 (2014) 22-27 Original Article The impact of HMG on follicular fluid hormone levels, embryo quality and IVF outcome Gokce Anik Ilhan a,*, Gozde Erkanli Senturk a, Ozgur Oktem
More informationDuration of progesterone-in-oil support after in vitro fertilization and embryo transfer: a randomized, controlled trial
Duration of progesterone-in-oil support after in vitro fertilization and embryo transfer: a randomized, controlled trial Christine S. Goudge, M.D., Theodore C. Nagel, M.D., and Mark A. Damario, M.D. Division
More informationThe effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study
Clinical research The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study Ashraf Moini 1,2, Shahrzad Zadeh Modarress 3, Elham Amirchaghmaghi
More informationInfertility Clinical Guideline
Infertility Clinical Guideline Ovarian Stimulation Guideline Purpose: To provide sufficient background regarding various ovarian stimulation protocols for In Vitro Fertilization cycles. Goal: To assist
More informationOvarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase
Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase Michael von Wolff, M.D., a Christian J. Thaler, M.D., b Torsten Frambach, M.D., c Cosima Zeeb,
More informationLH activity administration during the
LH activity administration during the luteal-follicular transition Richard Fleming On behalf of the Luveris Pre-treatment group University of Glasgow Scotland Androgens have a Paracrine action in the Early
More informationDoes ovulation triggering influence the risk for ovarian hyperstimulation syndrome?
Gerris Ch 20 06/12/2005 11:51 am Page 1 CHAPTER 20 Does ovulation triggering influence the risk for ovarian hyperstimulation syndrome? Shahar Kol INTRODUCTION Ovarian hyperstimulation syndrome (OHSS) is
More informationIVF Protocols: Hyper & Hypo-Responders, Implantation
IVF Protocols: Hyper & Hypo-Responders, Implantation Midwest Reproductive Symposium June 4-5, 4 2010 Subset : Hyper-Responders Mark R. Bush, MD, FACOG, FACS OBJECTIVE: Important goals for the PCOS patient
More informationEffects of HCG and LH on ovarian stimulation. Are they bioequivalent?
Effects of HCG and LH on ovarian stimulation Are they bioequivalent? Know the type of gonadotrophin required to have enough oocytes of good quality to achieve a healthy child FSH MAXIMIZE EFFICIENCY MINIMIZE
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Human Ovarian Steroidogenesis and Gonadotrophin Stimulation Johan
More informationThe serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins
Original Article Obstet Gynecol Sci 2018;61(2):242-246 https://doi.org/10.5468/ogs.2018.61.2.242 pissn 2287-8572 eissn 2287-8580 The serum estradiol/oocyte ratio in patients with breast cancer undergoing
More informationENDOCRINE CHARACTERISTICS OF ART CYCLES
ENDOCRINE CHARACTERISTICS OF ART CYCLES DOÇ. DR. SEBİHA ÖZDEMİR ÖZKAN KOCAELI UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF OBSTETRICS AND GYNECOLOGY, IVF UNIT 30.04.2014, ANTALYA INTRODUCTION The endocrine
More informationOvarian hyperstimulation syndrome (OHSS)
Ovarian hyperstimulation syndrome (OHSS) OHSS OHSS: exaggerated response to gonadotropins and hcg Characterized by: ovarian enlargement increased vascular permeability fluid accumulation in abdomen Associated
More information2013 Sep.; 24(3):
Journal of Reproduction & Contraception doi: 10.7669/j.issn.1001-7844.2013.03.0151 2013 Sep.; 24(3):151-158 E-mail: randc_journal@163.com Reducing the Trigger Dose of Human Chorionic Gonadotrophin Does
More informationBest practices of ASRM and ESHRE
Best practices of ASRM and ESHRE Late submission Cortina d Ampezzo, Italy 1-3 March 2012 A joint meeting between the American Society for Reproductive Medicine and the European Society of Human Reproduction
More informationInternational Journal of Women s Health and Reproduction Sciences Vol. 6, No. 2, April 2018, ISSN
http://www.ijwhr.net Open Access doi 10.15296/ijwhr.2018.31 Original Article International Journal of Women s Health and Reproduction Sciences Vol. 6, No. 2, April 2018, 187 191 ISSN 2330-4456 Comparison
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Infertility Injectables Table of Contents Coverage Policy... 1 General Background...16 Coding/Billing Information...20 References...20 Effective Date...
More informationUse of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to friendly IVF?
Human Reproduction Vol.17, No.8 pp. 2022 2026, 2002 Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to friendly IVF? J.B.Engel, M.Ludwig 1, R.Felberbaum,
More information2017 United HealthCare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1143-4 Program Prior Authorization/Notification Medication Menopur (menotropins) * P&T Approval Date 8/2014, 5/2015, 5/2016, 5/2017
More informationMaria A. Manzanares, M.D., Jose Lui Gomez-Palomares, M.D., Elisabetta Ricciarelli, M.D., and Eleuterio R. Hernandez, M.D., Ph.D.
Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol
More informationPediatrics, Obstetrics and Gynecology, University School of Medicine, Valencia University, Valencia, Spain
Delaying the initiation of progesterone supplementation until the day of fertilization does not compromise cycle outcome in patients receiving donated oocytes: a randomized study María-José Escribá, Ph.D.,
More informationReproductive FSH. Analyte Information
Reproductive FSH Analyte Information 1 Follicle-stimulating hormone Introduction Follicle-stimulating hormone (FSH, also known as follitropin) is a glycoprotein hormone secreted by the anterior pituitary
More informationTimur Giirgan, M.D.* Bulent Urman, M.D. Hakan Yarali, M.D. Hakan E. Duran, M.D.
FERTILITY AND STEFULI~ Vol. 68, No. 3, September 1997 Copyright 1997 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Published by Elsevier Science Inc. Follicle-stimulating
More informationThe Human Menstrual Cycle
The Human Menstrual Cycle Name: The female human s menstrual cycle is broken into two phases: the Follicular Phase and the Luteal Phase. These two phases are separated by an event called ovulation. (1)
More informationUnderstanding Infertility, Evaluations, and Treatment Options
Understanding Infertility, Evaluations, and Treatment Options Arlene J. Morales, M.D., F.A.C.O.G. Fertility Specialists Medical Group, Inc. What We Will Cover Introduction What is infertility? Briefly
More informationHana Park, Chung-Hoon Kim, Eun-Young Kim, Jei-Won Moon, Sung-Hoon Kim, Hee-Dong Chae, Byung-Moon Kang
Original Article Obstet Gynecol Sci 2015;58(6):481-486 http://dx.doi.org/10.5468/ogs.2015.58.6.481 pissn 2287-8572 eissn 2287-8580 Effect of second-line surgery on in vitro fertilization outcome in infertile
More informationwww.iffs-reproduction.org @IntFertilitySoc Int@FedFertilitySoc Conflict of interest none Outline Causes of ovulatory dysfunction Assessment of women with ovulatory dysfunction Management First line Second
More informationOocyte maturity and preimplantation development in relation to follicle diameter in gonadotropin-releasing hormone agonist or antagonist treatments
IN VITRO FERTILIZATION Oocyte maturity and preimplantation development in relation to follicle diameter in gonadotropin-releasing hormone agonist or antagonist treatments Daniela Nogueira, Ph.D., a Shevach
More informationA prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF
FVV IN OBGYN, 2012, 4 (2): 82-87 Original paper A prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF S. GORDTS,
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Recombinant versus urinary follicle-stimulating hormone in intrauterine insemination cycles: a prospective, randomized analysis of cost effectiveness Gerli S, Casini M L, Unfer V, Costabile L, Bini V,
More informationMilan Reljič, Ph.D., Veljko Vlaisavljević, Ph.D., Vida Gavrić, M.Sc., Borut Kovačič, Ph.D.,
FERTILITY AND STERILITY VOL. 75, NO. 3, MARCH 2001 Copyright 2001 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Value of the serum estradiol
More informationLink between effectiveness and cost data The costing was undertaken prospectively on the same patient sample that provided the effectiveness data.
Recombinant versus highly-purified, urinary follicle-stimulating hormone (r-fsh vs. HPuFSH) in ovulation induction: a prospective, randomized study with cost-minimization analysis Revelli A, Poso F, Gennarelli
More informationStudy on Several Factors Involved in IVF-ET of Human Beings
Study on Several Factors Involved in IVF-ET of Human Beings Lei X 1, Zhuoran W 1, Bin L 1, Huiming L 1, Hongxiu Z 1, Yajuan Z 1, Yingbo Q 1, Guixue Z 2 1 The First Clinical College of Harbin Medical University,
More informationEndometrial advancement after triggering with recombinant or urinary HCG: a randomized controlled pilot study
Reproductive BioMedicine Online (2010) 21, 50 55 www.sciencedirect.com www.rbmonline.com ARTICLE Endometrial advancement after triggering with recombinant or urinary HCG: a randomized controlled pilot
More informationIVF AND PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) WHAT THE COMMUNITY PHYSICIAN NEEDS TO KNOW
IVF AND PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) WHAT THE COMMUNITY PHYSICIAN NEEDS TO KNOW Jon Havelock, MD, FRCSC, FACOG Co-Director - PCRM Disclosure No conflict of interest in relation
More informationIn Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome
Original Article Effect of Laparoscopic Ovarian Drilling on Outcomes of In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome Maryam Eftekhar, M.D. 1, Razieh Deghani Firoozabadi,
More informationHow to make the best use of the natural cycle for frozen-thawed embryo transfer?
How to make the best use of the natural cycle for frozen-thawed embryo transfer? Ariel Weissman, MD IVF Unit, Dep. Ob/Gyn Wolfson Medical Center, Holon Sackler Faculty of Medicine, Tel Aviv University
More informationCONTROLLED OVARIAN HYPERSTIMULATION AND OOCYTE RETRIEVAL : CLINICAL INPUTS. DR Priyanka Sinha MD OB-GYN MUMBAI, INDIA
CONTROLLED OVARIAN HYPERSTIMULATION AND OOCYTE RETRIEVAL : CLINICAL INPUTS DR Priyanka Sinha MD OB-GYN MUMBAI, INDIA LEARNING OBJECTIVE Introduction Ovarian stimulation protocols Comparison of different
More informationAlternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment
Human Reproduction Vol., No.11 pp. 319 3197, 5 Advance Access publication July 1, 5. doi:.93/humrep/dei Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to
More informationIvf day 6 estradiol level
Ivf day 6 estradiol level Search It is also important to measure the estradiol on day 3. Day 2 is fine. The reason its day 3 is 15-20 years ago, the IVF medications were always started on day 3. Day 3
More informationPossible factors affecting the development of oocytes in in-vitro maturation
Human Reproduction Vol. 15, (Suppl. 5) pp. 11-17, 2000 Possible factors affecting the development of oocytes in in-vitro maturation Anne Lis Mikkelsen 1 ' 2, Steven Smith 1 and Svend Lindenberg 1 ^he Fertility
More informationInfluence ovarian stimulation on oocyte and embryo quality. Prof.Dr. Bart CJM Fauser
Influence ovarian stimulation on oocyte and embryo quality Prof.Dr. Bart CJM Fauser How to balance too much vs too little? Lecture Outline Context ovarian stimulation Impact ovarian stimulation on oocyte
More informationAndrogen priming using aromatase inhibitor and hcg during early-follicular-phase GnRH antagonist down-regulation in modified antagonist protocols
Human Reproduction Vol.21, No.10 pp. 2593 2600, 2006 Advance Access publication June 19, 2006. doi:10.1093/humrep/del221 Androgen priming using aromatase inhibitor and hcg during early-follicular-phase
More informationJournal of Gynecology & Reproductive Medicine
Research Article ISSN: 2576-2842 Journal of Gynecology & Reproductive Medicine Shorter Length of Gonadotropin Stimulation is Associated with Adverse IV F outcomes: A Retrospective Analysis Peter Kovacs,
More informationHighly purified hmg versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists a randomized study
Human Reproduction Vol.23, No.10 pp. 2346 2351, 2008 Advance Access publication on June 25, 2008 doi:10.1093/humrep/den220 Highly purified hmg versus recombinant FSH in ovarian hyperstimulation with GnRH
More informationMinimal stimulation using recombinant follicle-stimulating hormone and a gonadotropin-releasing hormone antagonist in women of advanced age
FERTILITY AND STERILITY VOL. 81, NO. 4, APRIL 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Minimal stimulation using recombinant
More informationEndometrial Preparation for Frozen Embryo Transfer (FET) Zitao Liu, MD, PhD New Hope Fertility Center, NY
Endometrial Preparation for Frozen Embryo Transfer (FET) Zitao Liu, MD, PhD New Hope Fertility Center, NY Natural Cycle FET Protocol for endometrial preparation N FET, including modified N FET HRT FET:
More informationSTIMULATION AND OVULATION TRIGGERING
STIMULATION AND OVULATION TRIGGERING Professor IOANNIS E. MESSINIS MD, PhD (Aberdeen, UK), FRCOG (UK) Department of Obs/Gynae University of Thessaly Larissa, GREECE DISCLOSURE Nothing to disclose Learning
More informationDr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain. Declared no potential conflict of interest
Dr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain Declared no potential conflict of interest Is there a role for LH in elderly patients? Dr. Ernesto Bosch Instituto Valenciano de Infertilidad.
More informationLars G.Westergaard 1, Karin Erb, Steen Laursen, Per E.Rasmussen and Sven Rex
Human Reproduction vol.11 no.6 pp. 1209-1213, 19% The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertuization in
More informationFixed Schedule for in vitro Fertilization and Embryo Transfer: Comparison of Outcome between the Short and the Long Protocol
Yamanashi Med. J. 14(3), 77 ~ 82, 1999 Original Article Fixed Schedule for in vitro Fertilization and Embryo Transfer: Comparison of Outcome between the Short and the Long Protocol Tsuyoshi KASAI and Kazuhiko
More informationAsimina Tavaniotou 1, Carola Albano 1, Johan Smitz 1 and Paul Devroey 1,2
Human Reproduction Vol.16, No.4 pp. 663 667, 2001 Comparison of LH concentrations in the early and midluteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist
More informationEndocrinology of the Female Reproductive Axis
Endocrinology of the Female Reproductive Axis girlontheriver.com Geralyn Lambert-Messerlian, PhD, FACB Professor Women and Infants Hospital Alpert Medical School at Brown University Women & Infants BROWN
More informationPhases of the Ovarian Cycle
OVARIAN CYCLE An ovary contains many follicles, and each one contains an immature egg called an oocyte. A female is born with as many as 2 million follicles, but the number is reduced to 300,000 to 400,000
More informationCASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen?
CASE 41 A 19-year-old woman presents to her gynecologist with complaints of not having had a period for 6 months. She reports having normal periods since menarche at age 12. She denies sexual activity,
More informationVaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization embryo transfer
Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization embryo transfer Mohamed F. Mitwally, M.D., H.C.L.D., a Michael P. Diamond,
More informationThe emergence of Personalized Medicine protocols for IVF.
Individualising IVF: Introduction to the POSEIDON Concept Introduction The emergence of Personalized Medicine protocols for IVF. Differences between patients: age, ovarian reserve, BMI or presence of ovarian
More informationCommon protocols in intra-uterine insemination cycles
Common protocols in intra-uterine insemination cycles Doç. Dr. Candan İltemir Duvan Turgut Özal Üniversitesi Tıp Fakültesi Kadın Hastalıkları ve Doğum AD Ovulation induction with intra-uterine insemination
More information